Last reviewed · How we verify
Pac-CB
At a glance
| Generic name | Pac-CB |
|---|---|
| Also known as | combo CB-839 and Paclitaxel |
| Sponsor | Calithera Biosciences, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) (PHASE2)
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pac-CB CI brief — competitive landscape report
- Pac-CB updates RSS · CI watch RSS
- Calithera Biosciences, Inc portfolio CI